222 related articles for article (PubMed ID: 9617787)
1. Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease.
Cheng FC; Kuo JS; Chia LG; Dryhurst G
J Neural Transm (Vienna); 1996; 103(4):433-46. PubMed ID: 9617787
[TBL] [Abstract][Full Text] [Related]
2. Homovanillic acid in CSF of mild stage Parkinson's disease patients correlates with motor impairment.
Stefani A; Pierantozzi M; Olivola E; Galati S; Cerroni R; D'Angelo V; Hainsworth AH; Saviozzi V; Fedele E; Liguori C
Neurochem Int; 2017 May; 105():58-63. PubMed ID: 28108196
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP
J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186
[TBL] [Abstract][Full Text] [Related]
4. Unresponsiveness to L-DOPA in parkinsonian patients: a study of homovanillic acid concentration in the cerebrospinal fluid.
Nishi K; Kondo T; Narabayashi H; Takubo H; Muramoto S; Araki H
J Neurol Sci; 1989 Aug; 92(1):65-70. PubMed ID: 2475587
[TBL] [Abstract][Full Text] [Related]
5. [Salsolinol, 3-O-methyl-dopa and homovanillic acid in the cerebrospinal fluid of Parkinson patients].
Krygowska-Wajs A; Szczudlik A; Antkiewicz-Michaluk L; Romańska I; Vetulani J
Neurol Neurochir Pol; 1997; 31(5):875-85. PubMed ID: 9513952
[TBL] [Abstract][Full Text] [Related]
6. Monoamines and their metabolites in plasma and lumbar cerebrospinal fluid of Chinese patients with Parkinson's disease.
Chia LG; Cheng FC; Kuo JS
J Neurol Sci; 1993 Jun; 116(2):125-34. PubMed ID: 8336158
[TBL] [Abstract][Full Text] [Related]
7. Markers of dopamine metabolism in Parkinson's disease. The Parkinson Study Group.
LeWitt PA; Galloway MP; Matson W; Milbury P; McDermott M; Srivastava DK; Oakes D
Neurology; 1992 Nov; 42(11):2111-7. PubMed ID: 1436520
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Parkinson Study Group.
Arch Neurol; 1995 Mar; 52(3):237-45. PubMed ID: 7872875
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, redox properties, in vivo formation, and neurobehavioral effects of N-acetylcysteinyl conjugates of dopamine: possible metabolites of relevance to Parkinson's disease.
Shen XM; Xia B; Wrona MZ; Dryhurst G
Chem Res Toxicol; 1996; 9(7):1117-26. PubMed ID: 8902266
[TBL] [Abstract][Full Text] [Related]
10. CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease.
LeWitt P; Schultz L; Auinger P; Lu M;
Brain Res; 2011 Aug; 1408():88-97. PubMed ID: 21784416
[TBL] [Abstract][Full Text] [Related]
11. 14C-homovanillic acid in the cerebrospinal fluid of parkinsonian patients after intravenous 14C-L-dopa.
Extein I; Van Woert M; Roth RH; Bowers MB
Biol Psychiatry; 1976 Apr; 11(2):227-32. PubMed ID: 971447
[TBL] [Abstract][Full Text] [Related]
12. Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease.
Lunardi G; Galati S; Tropepi D; Moschella V; Brusa L; Pierantozzi M; Stefani A; Rossi S; Fornai F; Fedele E; Stanzione P; Hainsworth AH; Pisani A
Parkinsonism Relat Disord; 2009 Jun; 15(5):383-9. PubMed ID: 19010710
[TBL] [Abstract][Full Text] [Related]
13. Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.
Yamamoto T; Uchiyama T; Higuchi Y; Asahina M; Hirano S; Yamanaka Y; Kuwabara S
PLoS One; 2015; 10(9):e0138462. PubMed ID: 26394059
[TBL] [Abstract][Full Text] [Related]
14. Markers of dopamine depletion and compensatory response in striatum and cerebrospinal fluid.
Loeffler DA; LeWitt PA; DeMaggio AJ; Juneau PL; Milbury PE; Matson WR
J Neural Transm Park Dis Dement Sect; 1995; 9(1):45-53. PubMed ID: 7605589
[TBL] [Abstract][Full Text] [Related]
15. [The concentration of homovanillic acid and leucine-enkephalin in the lumbar CSF of patients with Parkinson's disease before and after madopar treatment].
Liu DK
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1989 Apr; 22(2):95-8, 126-7. PubMed ID: 2791764
[TBL] [Abstract][Full Text] [Related]
16. Elevated cerebrospinal fluid ratios of cysteinyl-dopamine/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies.
Goldstein DS; Holmes C; Sullivan P; Jinsmaa Y; Kopin IJ; Sharabi Y
Parkinsonism Relat Disord; 2016 Oct; 31():79-86. PubMed ID: 27474472
[TBL] [Abstract][Full Text] [Related]
17. Further insights into the influence of L-cysteine on the oxidation chemistry of dopamine: reaction pathways of potential relevance to Parkinson's disease.
Shen XM; Dryhurst G
Chem Res Toxicol; 1996 Jun; 9(4):751-63. PubMed ID: 8831820
[TBL] [Abstract][Full Text] [Related]
18. Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson's disease.
Poceta JS; Parsons L; Engelland S; Kripke DF
Sleep Med; 2009 Jan; 10(1):129-33. PubMed ID: 18207455
[TBL] [Abstract][Full Text] [Related]
19. The significance of 3-O-methyldopa concentrations in the cerebrospinal fluid in the pathogenesis of wearing-off phenomenon in Parkinson's disease.
Tohgi H; Abe T; Kikuchi T; Takahashi S; Nozaki Y
Neurosci Lett; 1991 Oct; 132(1):19-22. PubMed ID: 1787913
[TBL] [Abstract][Full Text] [Related]
20. Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease.
Moser A; Siebecker F; Vieregge P; Jaskowski P; Kömpf D
J Neural Transm (Vienna); 1996; 103(4):421-32. PubMed ID: 9617786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
